SCHEMBL2183102

SCHEMBL2183102

CS(=O)(=O)c1cccc(COc2cc3ncnc(NCCO)c3cc2Br)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 3/20 0.44
EGFR P00533 8/20 0.41
HTT P42858 3/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
LCK P06239 1/20 0.40
ENPP1 P22413 3/20 0.40
RAF1 P04049 1/20 0.40
MEN1 O00255 1/20 0.39
STAT3 P40763 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AURKA O14965 1/20 0.39
PIP4K2C Q8TBX8 1/20 0.39
PDE5A O76074 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707540 0.94 LMNA (0.46) LMNAMAPTMAPK1EGFRHTT
SCHEMBL13536721 0.91 MAPK1 (0.44) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL2182737 0.90 ALDH1A1 (0.49) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL2184357 0.89 EGFR (0.43) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL1842823 0.89 GAA (0.44) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL1706635 0.86 LMNA (0.39) LMNAMAPTMAPK1EGFRHTT
SCHEMBL2184566 0.85 SLC6A4 (0.40) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL1841173 0.85 HTT (0.45) LMNAEGFRHTTKDM4EHPGD
SCHEMBL1707897 0.83 ALDH1A1 (0.49) LMNAMAPK1EGFRHTTKDM4E
SCHEMBL1839128 0.83 NSD2 (0.46) LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841311-B2 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-23 US disclosed
US-8841311-B2 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-23 US disclosed
US-8841311-B2 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-23 US disclosed
EP-2321284-B1 SULFONE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE-MODULATORS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES Bayer Pharma AG (DE) 2012-05-09 EP disclosed
US-20110166168-A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-07 US disclosed
US-20110166168-A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-07 US disclosed
US-20110166168-A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166168-A1 Sulphone-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments TPMT, IFNG, HLA-DRB1 LMNA 4875/4885MAPT 3160/4885MAPK1 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.